Axogen, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Axogen, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $187.34M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $159.01M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $138.58M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $127.36M | Mar 5, 2024 |
| FY2020 | Dec 31, 2020 | $32.50M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $33.43M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $22.12M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $24.26M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $28.16M | Mar 1, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.35M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $141.98M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $121.87M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $108.81M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $104.43M | Mar 5, 2024 |
| FY2020 | Dec 31, 2020 | $27.03M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $27.73M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $16.51M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $19.45M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $23.28M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.70M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($9.96M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($21.72M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($28.95M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($26.99M) | Mar 5, 2024 |
| FY2020 | Dec 31, 2020 | ($6.01M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($1.48M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($8.11M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($8.19M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($7.04M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.85M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($3.29M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($21.46M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($29.71M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($25.42M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($23.18M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($31.41M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($20.50M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($7.95M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | ($8.13M) | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.89M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $27.77M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $27.34M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $25.63M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $24.18M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $17.85M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $17.51M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $11.77M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $6.70M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $4.21M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $812.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.54M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($5.72M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($16.07M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($13.41M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($9.63M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($19.87M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($17.86M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($9.24M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | ($11.24M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.75M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.10M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $13.87M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $20.08M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $27.81M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $21.91M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $4.66M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $6.28M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.11M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $931.0K | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $221.69M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $203.73M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $196.83M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $195.39M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $208.02M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $201.38M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $154.64M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $160.17M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $58.88M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $46.36M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.84M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $99.82M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $101.16M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $94.39M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $95.47M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $78.23M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $22.49M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $13.19M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $33.69M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $31.44M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.85M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $103.91M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $95.67M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $101.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $112.55M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $123.15M | Mar 5, 2024 |
| FY2022 | Dec 31, 2019 | $132.15M | Mar 14, 2023 |
| FY2021 | Dec 31, 2018 | $146.98M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $25.18M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $14.92M | Feb 24, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $170.0K | Mar 15, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Mar 15, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($306.96M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($291.26M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($281.30M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($259.58M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($230.63M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($203.65M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($179.86M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($150.73M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | ($128.33M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($117.88M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.55M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $27.55M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $31.02M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $15.28M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $32.76M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $48.77M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $35.72M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $24.29M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $36.51M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $30.01M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.39M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $47.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $46.60M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $45.71M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $44.82M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $32.03M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 1, 2021 |
| FY2012 | Dec 31, 2012 | $21.58M | Aug 7, 2013 |
| FY2012 | Dec 31, 2011 | $5.00M | Aug 7, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 44.15M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 43.12M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 42.45M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 41.74M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 40.62M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 39.59M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 38.90M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 34.35M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 33.01M | Feb 28, 2018 |